Global burden of 34 cancers among women in 2020 and projections to 2040 : Population-based data from 185 countries/territories
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
Globally women face inequality in cancer outcomes; for example, smaller improvements in life expectancy due to decreased cancer-related deaths than men (0.5 vs 0.8 years, 1981-2010). However, comprehensive global evidence on the burden of cancer among women (including by reproductive age spectrum) as well as disparities by region, remains limited. This study aimed to address these evidence gaps by considering 34 cancer types in 2020 and their projections for 2040. The cancer burden among women in 2020 was estimated using population-based data from 185 countries/territories sourced from GLOBOCAN. Mortality to Incidence Ratios (MIR), a proxy for survival, were estimated by dividing the age-standardised mortality rates by the age-standardised incidence rates. Demographic projections were performed to 2040. In 2020, there were an estimated 9.3 million cancer cases and 4.4 million cancer deaths globally. Projections showed an increase to 13.3 million (↑44%) and 7.1 million (↑60%) in 2040, respectively, with larger proportional increases in low- and middle-income countries. MIR among women was higher (poorer survival) in rare cancers and with increasing age. Countries with low Human Development Indexes (HDIs) had higher MIRs (69%) than countries with very high HDIs (30%). There was inequality in cancer incidence and mortality worldwide among women in 2020, which will further widen by 2040. Implementing cancer prevention efforts and providing basic cancer treatments by expanding universal health coverage through a human rights approach, expanding early screening opportunities and strengthening medical infrastructure are key to improving and ensuring equity in cancer control and outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
|---|---|
| Enthalten in: |
International journal of cancer - 154(2024), 8 vom: 15. Feb., Seite 1377-1393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bizuayehu, Habtamu Mellie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.34809 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365506524 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365506524 | ||
| 003 | DE-627 | ||
| 005 | 20240214232957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.34809 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM365506524 | ||
| 035 | |a (NLM)38059753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bizuayehu, Habtamu Mellie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global burden of 34 cancers among women in 2020 and projections to 2040 |b Population-based data from 185 countries/territories |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
| 520 | |a Globally women face inequality in cancer outcomes; for example, smaller improvements in life expectancy due to decreased cancer-related deaths than men (0.5 vs 0.8 years, 1981-2010). However, comprehensive global evidence on the burden of cancer among women (including by reproductive age spectrum) as well as disparities by region, remains limited. This study aimed to address these evidence gaps by considering 34 cancer types in 2020 and their projections for 2040. The cancer burden among women in 2020 was estimated using population-based data from 185 countries/territories sourced from GLOBOCAN. Mortality to Incidence Ratios (MIR), a proxy for survival, were estimated by dividing the age-standardised mortality rates by the age-standardised incidence rates. Demographic projections were performed to 2040. In 2020, there were an estimated 9.3 million cancer cases and 4.4 million cancer deaths globally. Projections showed an increase to 13.3 million (↑44%) and 7.1 million (↑60%) in 2040, respectively, with larger proportional increases in low- and middle-income countries. MIR among women was higher (poorer survival) in rare cancers and with increasing age. Countries with low Human Development Indexes (HDIs) had higher MIRs (69%) than countries with very high HDIs (30%). There was inequality in cancer incidence and mortality worldwide among women in 2020, which will further widen by 2040. Implementing cancer prevention efforts and providing basic cancer treatments by expanding universal health coverage through a human rights approach, expanding early screening opportunities and strengthening medical infrastructure are key to improving and ensuring equity in cancer control and outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adolescents and young adults | |
| 650 | 4 | |a age-standardised incidence rates | |
| 650 | 4 | |a age-standardised mortality rates | |
| 650 | 4 | |a burden | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a global cancer observatory | |
| 650 | 4 | |a menopause | |
| 650 | 4 | |a mortality-to-incidence ratio | |
| 650 | 4 | |a projections | |
| 650 | 4 | |a women | |
| 700 | 1 | |a Dadi, Abel F |e verfasserin |4 aut | |
| 700 | 1 | |a Hassen, Tahir A |e verfasserin |4 aut | |
| 700 | 1 | |a Ketema, Daniel Bekele |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Kedir Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kassa, Zemenu Y |e verfasserin |4 aut | |
| 700 | 1 | |a Amsalu, Erkihun |e verfasserin |4 aut | |
| 700 | 1 | |a Kibret, Getiye Dejenu |e verfasserin |4 aut | |
| 700 | 1 | |a Alemu, Addisu Alehegn |e verfasserin |4 aut | |
| 700 | 1 | |a Alebel, Animut |e verfasserin |4 aut | |
| 700 | 1 | |a Shifa, Jemal E |e verfasserin |4 aut | |
| 700 | 1 | |a Assefa, Yibeltal |e verfasserin |4 aut | |
| 700 | 1 | |a Tessema, Gizachew A |e verfasserin |4 aut | |
| 700 | 1 | |a Sarich, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Gebremedhin, Aster Ferede |e verfasserin |4 aut | |
| 700 | 1 | |a Bore, Meless G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 154(2024), 8 vom: 15. Feb., Seite 1377-1393 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:154 |g year:2024 |g number:8 |g day:15 |g month:02 |g pages:1377-1393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.34809 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 154 |j 2024 |e 8 |b 15 |c 02 |h 1377-1393 | ||